680209-72-7

Basic information

• Product Name: (S)-2-tert-Butoxycarbonylamino-3-(4-{4-[(1S,3R)-1-((S)-2-tert-butylcarbamoyl-4-pyridin-3-ylmethyl-piperazin-1-ylmethyl)-3-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-4-phenyl-butoxycarbonylamino]-butoxy}-phenyl)-propionic acid tert-butyl ester
• Synonyms: (S)-2-tert-Butoxycarbonylamino-3-(4-{4-[(1S,3R)-1-((S)-2-tert-butylcarbamoyl-4-pyridin-3-ylmethyl-piperazin-1-ylmethyl)-3-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-4-phenyl-butoxycarbonylamino]-butoxy}-phenyl)-propionic acid tert-butyl ester
• CAS NO: 680209-72-7
• Molecular Weight: 1048.33
• Mol File: 680209-72-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-tert-Butoxycarbonylamino-3-(4-{4-[(1S,3R)-1-((S)-2-tert-butylcarbamoyl-4-pyridin-3-ylmethyl-piperazin-1-ylmethyl)-3-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-4-phenyl-butoxycarbonylamino]-butoxy}-phenyl)-propionic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-tert-Butoxycarbonylamino-3-(4-{4-[(1S,3R)-1-((S)-2-tert-butylcarbamoyl-4-pyridin-3-ylmethyl-piperazin-1-ylmethyl)-3-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-4-phenyl-butoxycarbonylamino]-butoxy}-phenyl)-propionic acid tert-butyl ester(680209-72-7)
• EPA Substance Registry System: (S)-2-tert-Butoxycarbonylamino-3-(4-{4-[(1S,3R)-1-((S)-2-tert-butylcarbamoyl-4-pyridin-3-ylmethyl-piperazin-1-ylmethyl)-3-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-4-phenyl-butoxycarbonylamino]-butoxy}-phenyl)-propionic acid tert-butyl ester(680209-72-7)

Safety Data

• Hazardous Substances Data: 680209-72-7(Hazardous Substances Data)

Upstream product

• 150378-17-9 indinavir 
• 680209-40-9 N-Boc-Tyr-[O(CH₂)4NCO]-OtBu 
• 859170-42-6 N-Boc-Tyr[O(CH₂)4CO₂Et]-OtBu 
• 680209-39-6 N-Boc-Tyr-[O(CH₂)4COOH]-OtBu 
• 18938-60-8 (S)-tert-butyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxyphenyl)propanoate 

Relevant articles and documents

Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.

With the aim of improving the pharmacological properties of current protease inhibitors (PIs), the synthesis of various acyl and carbamate amino acid- or diglyceride-containing prodrugs derived from saquinavir, indinavir and nelfinavir, their in vitro stability with respect to hydrolysis and their anti-HIV activity in CEM-SS and MT4 cells have been investigated. l-Leucine (Leu) and l-phenylalanine (Phe) were connected through their carboxyl to the PIs while l-tyrosine (Tyr) was conjugated through its aromatic hydroxyl via various spacer units. Hydrolysis of the prodrug with liberation of the active free drug was crucial for antiviral activity. The Leu- and Phe-PI prodrugs released the active free drug very rapidly (half-lives of hydrolysis in buffer at 37 degree C of 3-4 h). The Tyr-PI conjugates with a -C(O)(CH(2))(4)- linker exhibited half-lives in the 40-70 h range and antiviral activities in the 21-325 nM range (from 2 to 22 nM for the free PIs). The chemically very stable carbamate "peptidomimetic" Tyr-PI prodrugs (no hydrolysis detected after 7 days in buffer) displayed a very low anti-HIV activity or were even inactive (EC(50) from 2300 nM to >10 microM). A very low antiviral activity was measured for the diglyceride-substituted saquinavir and for all of the disubstituted indinavir and nelfinavir prodrugs. All these prodrugs probably released the active parent PI too slowly under the antiviral assay conditions. These results combined with those from transepithelial transport studies (Rouquayrol et al., Pharm. Res., 2002, 19, 1704-1712) indicate that conjugation of amino acids (through their carboxyl) to the PIs constitutes a most appealing alternative which could improve the intestinal absorption of the PIs and reduce their recognition by efflux carriers.